DR-189 Validating the Utility of Meta-Analysis for Learning Translatable Predictive Models from in vitro Pharmacogenomics
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-189 Validating the Utility of Meta-Analysis for Learning Translatable Predictive Models from in vitro Pharmacogenomics
Several large initiatives have profiled cancer cell lines – lab grown models of disease – for their response to panels …
DR-186 Comprehensive evaluation of microbial organisms in human metastatic cancers and their influence on local immunity
We have shown that many human cancer types can be diagnosed using microbial DNA and RNA from patients’ primary tumors …
DR-181 Germline-Somatic Correlates for Cancer Drug Sensitivity and Survival
The goal of this project is to determine how germline mutations influence somatic mutation signatures, drug response, and survival. We …
DR-179 The impact of non-coding/regulatory mutations on cancer susceptibility and response to targeted therapies.
In terms of the research on genetic predisposition to cancers, recent advances in DNA sequencing technologies are facilitating the discovery …
DR-175 “Comparing metastatic and primary breast tumours through the lens of integrated subtypes – RNA-seq. DR-175 is an extension of DR-129”
This request is an extenstion of DR-129 to include RNA data. The Personalised Breast Cancer Program (PBCP) is an initiative …
DR-168 Defining mutational signatures of childhood cancer treatments
Numerous environmental triggers have been found to leave a mutational footprint on the DNA of human cancers. In our lab, …
DR-167 Health related quality of life and utilities in patients with locally advanced and metastatic cancer, treated with or without personalised treatment based on Whole Genome Sequencing.
The effect on health related quality of life (HRQoL) of patients treated with or without personalized treatment based on WGS …
DR-238 Accurate Discrimination of Major Cancer Types via Whole Genome Somatic Mutation Patterns
The two strongest factors predicting a human cancer’s clinical behaviour are the primary tumour’s anatomic organ of origin and its …
DR-232 Whole Genome Sequencing can classify diagnostically challenging tumors.
Cancer of Unknown Primary (CUP) accounts for approximately 3% of all metastatic cancers. Despite modern imaging techniques and extensive pathology …
DR-229 identifying patients that are resistant to EGFR-targeting therapy
EGFR-targeting therapies are used as anti-cancer agents. Not all patients respond well and side-effects can be significant. Therefore, biomarkers that …
DR-228 Artificial intelligence based predictive model for response to Immune Checkpoint inhibitors based on multiplex immunohistochemistry and whole genome analysis (ARCTIC)
Immunotherapy, like nivolumab and pembrolizumab, has drastically improved the survival of many cancer patients. However, some patients do not clinically …
DR-227 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
PurposeAfter treatment with a combination of chemotherapy and radiotherapy for esophageal cancer, the current standard treatment is to continue with …
Het feit dat het CPCT het samen met Hartwig Medical Foundation voor elkaar heeft gekregen om data, kennis en kunde van vrijwel alle Nederlandse ziekenhuizen te bundelen, is uniek en krijgt inmiddels ook internationale aandacht.